CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Project Number||pCODR 10209|
|Indication||Metastatic Castration Sensitive Prostate Cancer (mCSPC)|
|Funding Request||For the treatment of patients with metastatic castration sensitive prostate cancer|
|Review Status||Under Review|
|Pre Noc Submission||Yes|
|Manufacturer||Astellas Pharma Canada, Inc.|
|Sponsor||Astellas Pharma Canada, Inc.|
|Submission Date||February 24, 2020|
|Submission Deemed Complete||March 12, 2020|
|Submission Type||New Indication|
|Stakeholder Input Deadline ‡||March 9, 2020|
|Check-point meeting||April 23, 2020|
|pERC Meeting (target date)|
|Initial Recommendation Issued (target date)|
|Feedback Deadline (target date) ‡|
|pERC Reconsideration Meeting (target date)|
|Final Recommendation Issued (target date)|
|Notification to Implement Issued|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.